Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Drops By 25.0%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 900 shares, a decline of 25.0% from the February 13th total of 1,200 shares. Based on an average daily trading volume, of 32,000 shares, the short-interest ratio is presently 0.0 days.

SAB Biotherapeutics Stock Down 12.5 %

Shares of SABSW opened at $0.03 on Friday. The stock has a 50 day moving average of $0.06 and a 200 day moving average of $0.05. SAB Biotherapeutics has a 12 month low of $0.01 and a 12 month high of $0.18.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.